# A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.

> **NCT01128894** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 841 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **BIOLOGICAL:** albiglutide
- **DRUG:** liraglutide

## Key facts

- **NCT ID:** NCT01128894
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 841 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01128894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01128894, "A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01128894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*